Market Cap | 8.39B | P/E | 202.35 | EPS this Y | 360.00% | Ern Qtrly Grth | - |
Income | -1.04B | Forward P/E | 38.78 | EPS next Y | 64.30% | 50D Avg Chg | 8.00% |
Sales | 4.38B | PEG | 1.63 | EPS past 5Y | -2.13% | 200D Avg Chg | -10.00% |
Dividend | N/A | Price/Book | 1.78 | EPS next 5Y | 32.41% | 52W High Chg | -60.00% |
Recommedations | 3.00 | Quick Ratio | 1.74 | Shares Outstanding | 181.46M | 52W Low Chg | 48.00% |
Insider Own | 0.59% | ROA | 0.04% | Shares Float | 180.30M | Beta | 1.16 |
Inst Own | 93.25% | ROE | -25.39% | Shares Shorted/Prior | 9.51M/8.53M | Price | 46.54 |
Gross Margin | 21.75% | Profit Margin | -23.81% | Avg. Volume | 4,534,559 | Target Price | 60.75 |
Oper. Margin | 9.15% | Earnings Date | Nov 13 | Volume | 1,895,705 | Change | 0.06% |
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
Baird | Neutral | Sep 24, 24 |
William Blair | Market Perform | Sep 3, 24 |
RBC Capital | Sector Perform | Jul 11, 24 |
Barclays | Equal-Weight | Jun 28, 24 |
Stephens & Co. | Equal-Weight | Apr 4, 24 |
RBC Capital | Sector Perform | Feb 20, 24 |
RBC Capital | Sector Perform | Feb 6, 24 |
UBS | Neutral | Feb 6, 24 |
Stephens & Co. | Equal-Weight | Feb 6, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
GREISCH JOHN J | Executive Chair Executive Chair | Aug 30 | Buy | 50.24 | 21,000 | 1,055,040 | 34,000 | 09/01/23 |
Maselli Alessandro | President & CEO President & CEO | Aug 23 | Sell | 44.83 | 2,071 | 92,843 | 88,004 | 08/25/23 |
Gunther Scott | SVP, Quality & Reg... SVP, Quality & Reg. Affairs | Aug 23 | Sell | 44.57 | 269 | 11,989 | 29,932 | 08/25/23 |
Grippo Michael J | SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. | Aug 23 | Sell | 44.5 | 390 | 17,355 | 24,449 | 08/25/23 |
Gennadios Aristippos | Group Pres. Pharma &.. Group Pres. Pharma & Consumer | Aug 23 | Sell | 44.49 | 396 | 17,618 | 96,552 | 08/25/23 |
Fasman Steven L | EVP & Chief Admin Of.. EVP & Chief Admin Officer | Aug 23 | Sell | 44.65 | 817 | 36,479 | 73,789 | 08/25/23 |
Carletti Lorenzo | SVP Global Ops Ph &.. SVP Global Ops Ph & Cons Hlth | Aug 23 | Sell | 44.71 | 216 | 9,657 | 8,746 | 08/25/23 |
Arnold Jonathan | SVP, CCO & Div. Head.. SVP, CCO & Div. Head BioP Del. | Aug 23 | Sell | 44.87 | 87 | 3,904 | 57,399 | 08/25/23 |
Hopson Ricky | Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div | Aug 23 | Sell | 44.56 | 276 | 12,299 | 22,040 | 08/25/23 |
Hawkeswood Thomas W | Pres. Pharma Prod De.. Pres. Pharma Prod Delivery Div | Aug 23 | Sell | 44.72 | 147 | 6,574 | 7,533 | 08/25/23 |
Lickfold Charles | SVP, CIO SVP, CIO | Aug 23 | Sell | 44.72 | 190 | 8,497 | 11,339 | 08/25/23 |
Hunt Patricia | Pres. Consumer Healt.. Pres. Consumer Health Div | Aug 23 | Sell | 44.77 | 106 | 4,746 | 11,289 | 08/25/23 |
Pravda Ricardo | Chief Transformation.. Chief Transformation Officer | Aug 23 | Sell | 44.47 | 379 | 16,854 | 30,224 | 08/25/23 |
Pravda Ricardo | Chief Transformation.. Chief Transformation Officer | Aug 01 | Sell | 47.14 | 269 | 12,681 | 19,739 | 08/03/23 |
Maselli Alessandro | President & CEO President & CEO | Aug 01 | Sell | 47.23 | 1,485 | 70,137 | 86,101 | 08/03/23 |
Lickfold Charles | SVP, CIO SVP, CIO | Aug 01 | Sell | 47.9 | 135 | 6,466 | 5,570 | 08/03/23 |
Fasman Steven L | EVP & Chief Admin Of.. EVP & Chief Admin Officer | Aug 01 | Sell | 47.24 | 1,637 | 77,332 | 60,216 | 08/03/23 |
Boerman Manja | Pres. BioModalities.. Pres. BioModalities Division | May 01 | Sell | 49.86 | 1,446 | 72,098 | 14,414 | 05/03/23 |
Hopson Ricky | Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div | Jan 23 | Sell | 49.36 | 643 | 31,738 | 16,452 | 01/25/23 |
Boerman Manja | Pres. BioModalities.. Pres. BioModalities Division | Dec 05 | Sell | 51.70 | 780 | 40,326 | 15,860 | 12/07/22 |
Grippo Michael J | SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. | Oct 31 | Sell | 65.83 | 2,451 | 161,349 | 17,792 | 11/02/22 |
Hopson Ricky | Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div | Aug 31 | Sell | 89.59 | 2,216 | 198,531 | 17,095 | 09/02/22 |
Riley Michael A. | Pres. Bio Product De.. Pres. Bio Product Delivery Div | Aug 26 | Sell | 104.07 | 2,491 | 259,238 | 6,592 | 08/30/22 |
Gunther Scott | SVP, Quality & Reg... SVP, Quality & Reg. Affairs | Aug 26 | Sell | 104.07 | 1,639 | 170,571 | 23,988 | 08/30/22 |
Schmidt Kay A | SVP, Enterprise Func.. SVP, Enterprise Functions | Aug 24 | Sell | 103.04 | 1,321 | 136,116 | 17,388 | 08/26/22 |
Riley Michael A. | Pres. Bio Product De.. Pres. Bio Product Delivery Div | Aug 24 | Sell | 103.04 | 1,482 | 152,705 | 9,083 | 08/26/22 |
Pravda Ricardo | SVP & Chief HR Offic.. SVP & Chief HR Officer | Aug 24 | Sell | 103.04 | 1,747 | 180,011 | 20,008 | 08/26/22 |
Maselli Alessandro | President & CEO President & CEO | Aug 24 | Sell | 103.04 | 4,646 | 478,724 | 41,190 | 08/26/22 |
Hunt Patricia | Pres. Consumer Healt.. Pres. Consumer Health Div | Aug 24 | Sell | 103.04 | 339 | 34,931 | 9,315 | 08/26/22 |
Hopson Ricky | Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div | Aug 24 | Sell | 103.04 | 1,517 | 156,312 | 19,311 | 08/26/22 |
Hawkeswood Thomas W | Pres. Pharma Prod De.. Pres. Pharma Prod Delivery Div | Aug 24 | Sell | 103.04 | 671 | 69,140 | 6,294 | 08/26/22 |
Gunther Scott | SVP, Quality & Reg... SVP, Quality & Reg. Affairs | Aug 24 | Sell | 103.04 | 1,840 | 189,594 | 25,627 | 08/26/22 |
Grippo Michael J | SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. | Aug 24 | Sell | 103.04 | 1,670 | 172,077 | 20,243 | 08/26/22 |
Gennadios Aristippos | Group Pres. Pharma &.. Group Pres. Pharma & Consumer | Aug 24 | Sell | 103.04 | 1,645 | 169,501 | 86,769 | 08/26/22 |
Gargiulo Mario | SVP Global Ops Biolo.. SVP Global Ops Biologics | Aug 24 | Sell | 103.04 | 1,586 | 163,421 | 6,354 | 08/26/22 |
Fasman Steven L | EVP & Chief Admin Of.. EVP & Chief Admin Officer | Aug 24 | Sell | 103.04 | 4,811 | 495,725 | 61,853 | 08/26/22 |
Chiminski John R | Executive Chair Executive Chair | Aug 24 | Sell | 103.04 | 38,934 | 4,011,759 | 229,888 | 08/26/22 |
Castellano Thomas P | SVP, Chief Financial.. SVP, Chief Financial Officer | Aug 24 | Sell | 103.04 | 1,414 | 145,699 | 20,099 | 08/26/22 |
Carletti Lorenzo | SVP Global Ops Ph &.. SVP Global Ops Ph & Cons Hlth | Aug 24 | Sell | 103.04 | 1,033 | 106,440 | 4,985 | 08/26/22 |
Boerman Manja | Pres. BioModalities.. Pres. BioModalities Division | Aug 24 | Sell | 103.04 | 3,296 | 339,620 | 16,640 | 08/26/22 |
Arnold Jonathan | SVP & Chief Commerci.. SVP & Chief Commercial Ofcr | Aug 24 | Sell | 103.04 | 384 | 39,567 | 55,958 | 08/26/22 |
Schmidt Kay A | SVP, Enterprise Func.. SVP, Enterprise Functions | Jul 26 | Sell | 106.9 | 323 | 34,529 | 13,455 | 07/28/22 |
Pravda Ricardo | SVP & Chief HR Offic.. SVP & Chief HR Officer | Jul 26 | Sell | 106.9 | 427 | 45,646 | 15,337 | 07/28/22 |
Maselli Alessandro | President & CEO President & CEO | Jul 26 | Sell | 106.9 | 816 | 87,230 | 25,083 | 07/28/22 |
Hopson Ricky | Pres, Clinical Dev &.. Pres, Clinical Dev & Supply | Jul 26 | Sell | 107.29 | 903 | 96,883 | 17,095 | 07/28/22 |
Gunther Scott | SVP, Quality & Reg... SVP, Quality & Reg. Affairs | Jul 26 | Sell | 107.29 | 844 | 90,553 | 22,350 | 07/28/22 |
Grippo Michael J | SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. | Jul 26 | Sell | 107.29 | 797 | 85,510 | 17,023 | 07/28/22 |
Gennadios Aristippos | Group Pres. Pharma &.. Group Pres. Pharma & Consumer | Jul 26 | Sell | 106.9 | 403 | 43,081 | 79,784 | 07/28/22 |
Gargiulo Mario | SVP Global Ops Biolo.. SVP Global Ops Biologics | Jul 26 | Sell | 106.9 | 969 | 103,586 | 3,671 | 07/28/22 |
Fasman Steven L | EVP & Chief Admin Of.. EVP & Chief Admin Officer | Jul 26 | Sell | 106.9 | 2,546 | 272,167 | 53,721 | 07/28/22 |